Fluorouracil

Fluorouracil is a nucleoside metabolic inhibitor indicated for the treatment of patients with

• Adenocarcinoma of the Colon and Rectum ( 1.1 )
• Adenocarcinoma of the Breast ( 1.2 )
• Gastric Adenocarcinoma ( 1.3 )
• Pancreatic Adenocarcinoma ( 1.4 )

1.1 Adenocarcinoma of the Colon and Rectum .

1.2 Adenocarcinoma of the Breast .

1.3Gastric

Adenocarcinoma .

1.4Pancreatic

Adenocarcinoma .

None. None.

• Increased Risk of Serious or Fatal Adverse Reactions in Patients with Low or Absent Dipyrimidine Dehydrogenase Activity: Withhold or permanently discontinue Fluorouracil in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of dipyrimidine dehydrogenase (DPD) activity. No Fluorouracil dose has been proven safe in patients with absent DPD activity. ( 5.1 )
• Cardiotoxicity: Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction/ischemia, arrhythmia, and heart failure. Withhold Fluorouracil for cardiac toxicity. ( 5.2 )
• Hyperammonemic Encephalopathy: Altered mental status, confusion, disorientation, coma, or ataxia with elevated serum ammonia level can occur within 72 hours of initiation of Fluorouracil. Withhold Fluorouracil and initiate ammonia-lowering therapy. ( 5.3 )
• Neurologic Toxicity: Fluorouracil can cause acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances. Withhold Fluorouracil for neurologic toxicity. ( 5.4 )